NASDAQ-NMS:IMAB

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Friday, April 5, 2024
EST, Conference, Cancer, Pharmaceutical industry

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

Key Points: 
  • ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
  • Thursday, April 11 at 10:15 a.m. EST

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Retrieved on: 
Monday, November 6, 2023
EST, Conference, Patient, Piper Sandler Companies, Pharmaceutical industry, Reinsurance

ROCKVILLE, Md.

Key Points: 
  • ROCKVILLE, Md.
  • and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.
  • Details of the conferences and management presentation are as follows:
    Tuesday, November 14th at 10:30 a.m. GMT (5:30 a.m. EST)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

Retrieved on: 
Wednesday, November 1, 2023
Therapy, Society for Immunotherapy of Cancer, Immunotherapy, SITC, Stomach, Patient, Abstract, Annual general meeting, Poster, Pharmaceutical industry, MD

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer's (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, California.

Key Points: 
  • ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy of Cancer's (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, California.
  • The full text of the abstracts has been released on the SITC website, and the posters will be available on the Company's website following the conclusion of SITC 2023.
  • Details of the poster presentations are as follows:
    Givastomig, a novel Claudin18.2/4-1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Congress, European Society for Medical Oncology, ESMO, Oncology, CET, Monoclonal antibody, Patient, Pharmaceutical industry, Vaccine

ROCKVILLE, Md.

Key Points: 
  • ROCKVILLE, Md.
  • and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, on Monday, October 23 at 12:00 p.m. CET.
  • First-In-Human Phase I Study of Givastomig, A Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

Retrieved on: 
Tuesday, August 8, 2023
EST, Pharmaceutical industry, News

ROCKVILLE, Md.

Key Points: 
  • ROCKVILLE, Md.
  • and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023, and host a conference call to discuss the results and provide corporate updates at 8:00 a.m. EST.
  • Investors and analysts are invited to join the conference call at 8:00 a.m. EST on August 17 via Zoom:

I-Mab Announces the Appointment of Raj Kannan as CEO

Retrieved on: 
Thursday, June 22, 2023
Growth, Aerie Pharmaceuticals, Patient, Pharmaceutical industry, Fine chemical

This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide.

Key Points: 
  • This appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide.
  • Raj Kannan has over 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO.
  • Mr. Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally.
  • "I am very pleased to welcome Mr. Raj Kannan on board.

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

Retrieved on: 
Monday, March 20, 2023
Lishui, United, WeChat, EST, Patient, Pharmaceutical industry

and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

Key Points: 
  • and SHANGHAI, China, March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday, March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.
  • For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

Retrieved on: 
Wednesday, October 5, 2022
LinkedIn, U.S. Securities and Exchange Commission, CD73, B-cell lymphoma, Form 20-F, Macrophage, AML, SITC, NDA, Degenerative disease, Neoplasm, MDS, Patient, Lishui, Twitter, Annual report, Myelodysplastic syndrome, Technology, Private Securities Litigation Reform Act, B cell, Tumor microenvironment, Anemia, Acute leukemia, Company, NHL, Adenosine, Safety, 2021 Essex County Council election, AMP, Intellectual property, CD47, COVID-19, WeChat, Cancer, Risk, Vaccine, Pharmaceutical industry

ET on Monday, November 7, 2022, and the posters will be available on the Company's website on November 12, 2022.

Key Points: 
  • ET on Monday, November 7, 2022, and the posters will be available on the Company's website on November 12, 2022.
  • CD47 antibody blocks this signal and enables macrophages to attack tumor cells.
  • However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells.
  • Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
Lishui, COVID-19, NDA, Technology, Safety, Degenerative disease, Anemia, Macrophage, WeChat, Myelodysplastic syndrome, Risk, AML, MDS, LinkedIn, B-cell lymphoma, Acute leukemia, NHL, U.S. Securities and Exchange Commission, Company, CD47, Cancer, Twitter, Neoplasm, Intellectual property, Annual report, Private Securities Litigation Reform Act, Form 20-F, Patient, Pharmaceutical industry

CD47 antibody blocks this signal and enables macrophages to attack tumor cells.

Key Points: 
  • CD47 antibody blocks this signal and enables macrophages to attack tumor cells.
  • However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells.
  • Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

Retrieved on: 
Friday, August 19, 2022
U.S. Securities and Exchange Commission, Lishui, Forward-looking statement, Patient, Company, Twitter, GMP, Private Securities Litigation Reform Act, Form 20-F, Annual report, LinkedIn, Terminology, WeChat, Fine chemical, Audit

GAITHERSBURG, Md. and SHANGHAI, Aug. 19, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022. The Company's management will host conference calls with investors to provide updates on recent pipeline development, upcoming milestones, and potential implementation of a comprehensive share purchase program by the Company and current shareholders.

Key Points: 
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • You can identify forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements.
  • Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements.
  • Actual results may differ materially from those contemplated by the forward-looking statements as a result of various important factors.